2 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Metastatic Triple Negative Breast Cancers: new trials by email Literature Review of Metastatic Triple Negative Breast Cancers trials Research Report on Metastatic Triple Negative Breast Cancers
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sac-TMT for Active TNBC Brain Metastases Sacituzumab tirumotecan - Metastatic Triple Negative Breast Cancers | Phase 2 | Not yet recruiting | Yale University | 20 | 2026-08-01 | 2026-07-24 |
| Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer Specimen collection, Non-Investigational Antibody-Drug Conjugates (ADC), Medical Record Review - HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma | Recruiting | University of California, San Francisco | 100 | 2025-10-08 | 2026-10-16 | |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel - Locally Advanced Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Active not recruiting | BioNTech SE | 83 | 2024-08-26 | 2026-06-30 |
| Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START) Talazoparib, Selinexor - Advanced Refractory Solid Tumors, Advanced Triple Negative Breast Cancers | Phase 1 / Phase 2 | Recruiting | National University Hospital, Singapore | 63 | 2021-03-01 | 2025-07-25 |
Triple Negative Breast Neoplasms (4) · Breast Neoplasms (2) · Brain Neoplasms (1)
Breast Diseases (4) · Neoplasms (4) · Neoplasms by Site (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Breast Neoplasms (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Nervous System Diseases (1) · Nervous System Neoplasms (1)
Carboplatin (1) · Gemcitabine (1) · Paclitaxel (1) · Specimen Handling (1) · eribulin (1) · selinexor (1) · talazoparib (1)
BioNTech SE (1) · National University Hospital, Singapore (1) · University of California, San Francisco (1) · Yale University (1)
United States (3) · Australia (1) · Singapore (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Adriana Kahn, MD (1) · Laura Huppert, MD,BA (1) · Soo Chin Lee (1)